Brokerage firm Janney Capital Downgrades its rating on Clovis Oncology Inc(NASDAQ:CLVS). The shares have been rated Neutral. Previously, the analysts had a Buy rating on the shares. The rating by Janney Capital was issued on Sep 21, 2016.
In a different note, On Sep 21, 2016, Credit Suisse said it Upgrades its rating on Clovis Oncology Inc. In the research note, the firm Raises the price-target to $19.00 per share. The shares have been rated ‘Outperform’ by the firm. On Aug 24, 2016, SunTrust Robinson Humphrey said it Maintains its rating on Clovis Oncology Inc. In the research note, the firm Raises the price-target to $25.00 per share. The shares have been rated ‘Buy’ by the firm. SunTrust Robinson Humphrey said it Initiates Coverage on Clovis Oncology Inc, according to a research note issued on Aug 5, 2016. The shares have been rated ‘Buy’ by the firm.
Clovis Oncology Inc (CLVS) made into the market gainers list on Tuesdays trading session with the shares advancing 12.68% or 3.92 points. Due to strong positive momentum, the stock ended at $34.83, which is also near the day’s high of $35.75. The stock began the session at $31.44 and the volume stood at 78,47,227 shares. The 52-week high of the shares is $115.85 and the 52 week low is $11.57. The company has a current market capitalization of $1,341 M and it has 3,85,01,077 shares in outstanding.
Clovis Oncology Inc(CLVS) last announced its earnings results on Aug 8, 2016 for Fiscal Year 2016 and Q2.Earnings per share were $-2.07. Analysts had estimated an EPS of $-2.13.
Several Insider Transactions has been reported to the SEC. On Nov 3, 2015, Erle T Mast (Executive VP and CFO) sold 3,000 shares at $104.18 per share price.Also, On Oct 30, 2015, Lindsey Rolfe (officer ) sold 4,000 shares at $97.80 per share price.On Oct 16, 2015, Gillian C Ivers-read (officer ) sold 3,000 shares at $91.91 per share price, according to the Form-4 filing with the securities and exchange commission.
Clovis Oncology Inc. (Clovis) is a biopharmaceutical company focused on acquiring developing and commercializing anti-cancer agents in the United States Europe and additional international markets. The Company is developing three product candidates: Rociletinib Rucaparib and Lucitanib. Rociletinib an oral epidermal growth factor receptor (EGFR) is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib an oral inhibitor of poly (ADP-ribose) polymerase (PARP) is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3) vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.